MIRA Pharmaceuticals, Inc. (MIRA)
USD 1.05
(-1.87%)
USD 1.05
(-1.87%)
| Breakdown | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | - | - | - | - |
| Cost of Revenue | 8.52 Million | - | - | - |
| Gross Profit | -8.52 Million | - | - | - |
| Operating Expenses | 8.52 Million | 7.04 Million | 2.15 Million | 67.62 Thousand |
| Selling, General and Administrative Expenses | 6.95 Million | 2.99 Million | 770.11 Thousand | 52.98 Thousand |
| Research and Development Expenses | 1.57 Million | 2.35 Million | 684.44 Thousand | 14.64 Thousand |
| Other Expenses | - | -1.7 Million | -697.6 Thousand | - |
| Cost and Expenses | 8.52 Million | 7.04 Million | 2.15 Million | 67.62 Thousand |
| Operating Income | -8.52 Million | -7.04 Million | -2.15 Million | -67.63 Thousand |
| Interest Expense | 3.45 Million | 10.25 Thousand | 24.37 Thousand | 364.00 |
| Income Tax Expense | - | -7047.94 | -2152.16 | -202.89 |
| Earnings before Tax | -11.98 Million | -7.05 Million | -2.17 Million | -67.99 Thousand |
| Net Income | -11.98 Million | -7.05 Million | -2.17 Million | -67.99 Thousand |
| Earnings Per Share Basic | -0.65 | -0.48 | -0.15 | -0.00 |
| Earnings Per Share Diluted | -0.65 | -0.48 | -0.15 | -0.00 |
| Weighted Average Shares Outstanding | 18.56 Million | 14.74 Million | 14.74 Million | 14.74 Million |
| Weighted Average Shares Outstanding (Diluted) | 18.56 Million | 14.74 Million | 14.74 Million | 14.74 Million |
| Gross Margin | - | - | - | - |
| EBIT Margin | - | - | - | - |
| Profit Margin | - | - | - | - |
| EBITDA | - | -7.04 Million | -2.15 Million | - |
| Earnings Before Tax Margin | - | - | - | - |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | 1.73 Million | 1.76 Million | 8.52 Million | 8.52 Million | - | - |
| Gross Profit | -1.73 Million | -1.76 Million | -8.52 Million | -8.52 Million | - | - |
| Operating Expenses | 1.73 Million | 1.76 Million | 3.05 Million | 8.52 Million | 3.16 Million | 970.22 Thousand |
| Selling, General and Administrative Expenses | 1.11 Million | 1 Million | 2.66 Million | - | 2.14 Million | 1.07 Million |
| Research and Development Expenses | 614.46 Thousand | 762.27 Thousand | 387.12 Thousand | - | 1.01 Million | -101.01 Thousand |
| Other Expenses | - | - | 453.55 Thousand | - | - | - |
| Cost and Expenses | 1.73 Million | 1.76 Million | 3.05 Million | 8.52 Million | 3.16 Million | 970.22 Thousand |
| Operating Income | -1.73 Million | -1.76 Million | -3.05 Million | -8.52 Million | -3.16 Million | -970.22 Thousand |
| Interest Expense | 39.39 Thousand | 50.41 Thousand | 2.73 Million | -3.45 Million | 427.73 Thousand | 295.88 Thousand |
| Income Tax Expense | -1.73 Million | -1.76 Million | -3056.36 | -8526.05 | -3160.08 | -970.22 |
| Earnings before Tax | -1.69 Million | -1.71 Million | -5.78 Million | -11.98 Million | -3.58 Million | -1.26 Million |
| Net Income | -1.69 Million | -1.71 Million | -5.78 Million | -11.98 Million | -3.58 Million | -1.26 Million |
| Earnings Per Share Basic | -0.11 | -0.09 | -0.39 | - | -0.24 | -0.09 |
| Earnings Per Share Diluted | -0.11 | -0.09 | -0.39 | - | -0.24 | -0.09 |
| Weighted Average Shares Outstanding | 14.78 Million | 19.7 Million | 14.78 Million | 18.56 Million | 14.78 Million | 14.78 Million |
| Weighted Average Shares Outstanding (Diluted) | 14.78 Million | 19.7 Million | 14.78 Million | 18.56 Million | 14.78 Million | 14.78 Million |
| Gross Margin | - | - | - | - | - | - |
| EBIT Margin | - | - | - | - | - | - |
| Profit Margin | - | - | - | - | - | - |
| EBITDA | -1.73 Million | -1.76 Million | -3.05 Million | - | -3.16 Million | -970.22 Thousand |
| Earnings Before Tax Margin | - | - | - | - | - | - |
300234
ETP
CLDT-PA
SPACEINCUBA
AMMN
MFC